Abstract: A self-contained sterilization process biological indicator is provided. The indicator includes a housing. Test microorganisms disposed in the housing are enveloped by a wax composition. The wax composition comprises a long-chain (greater than C22) linear or branched alkyl or alkenyl alcohol, wherein the alkyl or alkenyl alcohol is not linked through an ester bond or an ether bond to a short chain alkyl or aryl (C1-C6) group, wherein the alkyl or alkenyl alcohol is not linked through an ester bond or an ether bond to a long chain (C8-C36) alkyl or alkenyl group, wherein the alkyl or alkenyl alcohol is not linked through an amide bond to a linear or branched long chain (C8-C36) alkyl or alkenyl amine or acid. The wax composition has a melting point between 78° C. and 120° C. Also contained in the housing are a nutrient composition and an openable container containing a liquid medium.

Abstract: Effective treatments of pain, such as chronic pelvic pain, for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of bupivacaine formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least thirty days, at least sixty days, at least one hundred days or at least one hundred and thirty-five days.

Abstract: Effective treatments of pain for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of a benzodiazepine, such as midazolam, formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days or at least one hundred and thirty-five days.

Abstract: Effective treatments of pain for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of baclofen formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least thirty days, at least sixty days, at least one hundred days or at least one hundred and thirty-five days.

Abstract: Antibody complexes including anti-A? antibodies conjugated with a sialic acid-containing molecule show improved bioavailability with no significant adverse effects on binding to amyloid beta.

Abstract: The invention describes poly(ortho ester) polymers that include at least one therapeutic compound in the polymer backbone. The therapeutic compound includes at least one phenol residue and an aliphatic alcohol residue or two or more phenolic residues.

Abstract: The present invention provides curable materials, medical devices incorporating such materials, wherein the curable materials are capable of releasing hydrolyzable leaving agents upon hydrolysis that can form agents (e.g., pharmaceutically active agents), and methods of making and using such materials and devices.

Abstract: The present invention provides curable materials, medical devices incorporating such materials, wherein the curable materials are capable of releasing hydrolyzable leaving agents upon hydrolysis that can form agents (e.g., pharmaceutically active agents), and methods of making and using such materials and devices.

Abstract: Effective treatments of pain for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of baclofen formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least thirty days, at least sixty days, at least one hundred days or at least one hundred and thirty-five days.

Abstract: Effective treatments of pain, such as chronic pelvic pain, for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of bupivacaine formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least thirty days, at least sixty days, at least one hundred days or at least one hundred and thirty-five days.

Abstract: Effective treatments of pain for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of a benzodiazepine, such as midazolam, formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days or at least one hundred and thirty-five days.

Abstract: A novel polymeric electrically insulating material that includes a linked voltage stabilizing agent. Also provided are methods of making the novel material and articles and devices that incorporate the novel material, particularly implantable medical devices.

Abstract: The present invention provides curable materials, medical devices incorporating such materials, wherein the curable materials are capable of releasing hydrolyzable leaving agents upon hydrolysis that can form agents (e.g., pharmaceutically active agents), and methods of making and using such materials and devices.

Abstract: Polymers that include silane-containing groups in soft segments, and optionally urethane groups, as well as medical devices and methods for making such compounds.

Abstract: Compounds that include diorgano groups having quaternary carbons, silicon-containing groups, and optionally urethane groups, urea groups, or combinations thereof (i.e., polyurethanes, polyureas, or polyurethane-ureas), as well as materials and methods for making such compounds.

Abstract: A high energy density capacitor comprising an organic polymeric dielectric material having a dielectric constant of at least about 7; wherein the organic polymeric dielectric material comprises polymerized alkyl (alpha-substituted)acrylate monomers having at least one dipole group; wherein when the monomers are polymerized, the dipole group is attached to the main polymeric chain through a heteroatom-containing linking group.

Abstract: A novel polymeric electrically insulating material that includes a linked voltage stabilizing agent. Also provided are methods of making the novel material and articles and devices that incorporate the novel material, particularly implantable medical devices.

Abstract: A high energy density capacitor comprising an organic polymeric dielectric material having a dielectric constant of at least about 7; wherein the organic polymeric dielectric material comprises polymerized alkyl (alpha-substituted)acrylate monomers having at least one dipole group; wherein when the monomers are polymerized, the dipole group is attached to the main polymeric chain through a heteroatom-containing linking group.